Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Celgene vs. Starbucks

By Mark Reeth and Max Macaluso – Mar 20, 2014 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We've collected the most popular companies among readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better Buy Tournament.

In today's ­first-round matchup of The Motley Fool Better Buy Tournament, Celgene (CELG) squares off against Starbucks (SBUX -0.08%) in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.

In the video below, Motley Fool analyst Max Macaluso makes the case for Celgene, a big biotech company, to move to the next round. After doubling in 2013, Celgene has faced a slow start to the year. However, the company's growing portfolio and pipeline make it a biotech to watch over the long term.

Starbucks has never been afraid of change, which is why Motley Fool Consumer Goods Editor Mark Reeth thinks it's one of the best companies on the market. Its mobile app has been a welcome addition to coffee drinkers' morning routines, with 10 million users signed up for the service. Starbucks also has been rapidly expanding overseas to great success: Revenue in the China/Asia-Pacific region was up 25% this past quarter, and that is only expected to grow. Lastly, the company is expanding its retail offerings and breaking into the tea market, which is just icing on the cake.

Watch these analysts square off in the video below and then vote for a winner. Then check out the other companies in the Motley Fool Better Buy Bracket

This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Cast your vote in the poll below the video!

Mark Reeth has no position in any stocks mentioned. Max Macaluso, Ph.D., owns shares of Celgene and Starbucks. The Motley Fool recommends Celgene and Starbucks. The Motley Fool owns shares of Starbucks. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.